Authorities bear down on Indian CROs; Allergan takes its AMD drug into Phase II;

@FierceBiotech: 21st Century drug bill triggers a DC dust-up over relaxed development regs. Report | Follow @FierceBiotech

@JohnCFierce: EuroBiotech: KDEV halves portfolio value, U.K. life sci funding hits 10-year high, CF gene therapy on the block. Report | Follow @JohnCFierce

@DamianFierce: ICYMI: Patrick Soon-Shiong tacitly creates another company every time he does anything. NantKwest?! Release | Follow @DamianFierce

> The FDA and World Health Organization have dialed up their scrutiny of Indian CROs after a pair of alarming study missteps have come to light over the past year. News

> Allergan ($AGN) is launching a Phase III trial of abicipar, a treatment for wet age‐related macular degeneration, triggering a $15 million payment for Molecular Partners, the drug's inventor. More

> Aerie Pharmaceuticals ($AERI) Chief Medical Officer Brian Levy has left the company. Item

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: CombiMatrix coasts toward growth with renewed sales push. Report | Follow @FierceMedDev

@StacyALawrence: Go big or go home: A call for FierceMedicalDevices' 2015 Fierce 15 nominations. ICYMI | Follow @StacyALawrence

@EmilyWFierce: Natera joins forces with University College London for lung cancer study. FierceDiagnostics story | Follow @EmilyWFierce

> Smith & Nephew strikes again, bolstering emerging markets with Russian trauma and orthopedics buy. Story

> Xagenic ropes in $15M for point-of-care testing system. Article

> CMS to test new reimbursement system for hip and knee replacements in the U.S. More

Pharma News

@FiercePharma: ImmuCell boosts Q2 sales guidance as inventory management improves. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: FDA says China staffer Dr. Lixia Wang was key to negotiating deal for more FDA inspection staff in China. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: AstraZeneca grabs $215M for GI drug rights in latest cash-generating deal. Article | Follow @CarlyHFierce

> Novartis' pay-for-performance Entresto plan has its critics--Express Scripts' Miller among them. Story

> U.K. cost gatekeeper changes its tune on Entyvio for Crohn's. More

> Fresenius companies fined £550,000 by U.K. court in patient death. News

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.